logo
Plus   Neg
Share
Email

Centamin FY19 Underlying EBITDA Rises; Maintains 2020 Production Outlook

Centamin Plc (CELTF.PK,CEY.L,CEE.TO) reported that its profit after tax for the twelve months ended 31 December 2019 increased 13% to $172.9 million. Basic earnings per share increased 17% to 7.59 US cents. Underlying EBITDA increased 10% to $284 million. The company noted that its fiscal 2019 financial performance further benefited from improved gold prices.

Fiscal year Gross revenues were $658.1 million, up 7% from prior year. A weaker third quarter, due to slower mining rates from a section of the open pit, impacted annual production performance of 480,528 ounces, which was up 2% from 2018.

Centamin maintained its 2020 full year guidance, targeting production between 510,000-540,000 ounces of gold, at cash costs between $630-$680 per ounce produced and AISC between $870-$920 per ounce sold. The company's 2020 capital expenditure is now expected to be in the range of $150 million-$170 million (previously $190 million).

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Avalon Furniture is recalling about 9,500 units of Cottage Town Bedroom Furniture collection sold through Rooms To Go due to violation of federal lead paint ban, the U.S. Consumer Product Safety Commission said in a statement. According to the agency, the base coat paint used on pieces within the furniture collection contains levels of lead that exceed the federal lead paint standard. Sanofi and Regeneron Pharmaceuticals, Inc. announced that the U.S. Phase 3 trial of arthritis drug Kevzara (sarilumab) 400 mg in COVID-19 patients requiring mechanical ventilation did not meet its primary and key secondary endpoints. In the trial, Kevzara was added to best supportive care compared to best supportive care alone (placebo). The companies have stopped the U.S. trial. Shares of Moderna Inc. (MRNA) slipped over 5% on Thursday after a report claimed that the biotechnology company's late-stage trial for a coronavirus vaccine will be delayed. Moderna is developing mRNA-1273 in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID). The...
RELATED NEWS
Follow RTT